Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis. METHODS: We conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight) administered subcutaneously at baseline, week 4, and week 8, as compared with placebo, in patients with moderate-to-severe prurigo nodularis and severe pruritus. Moderate-to-severe prurigo nodularis was defined as 20 or more nodules, and severe pruritus was defined as a mean score of at least 7 for the worst daily intensity of pruritus on the numerical rating scale (scores range from 0 [no itch] to 10 [worst itch imaginable]). The primary outcome was the percent change from baseline in the mean peak score for pruritus on the numerical rating scale at week 4. Secondary outcomes included additional measures of itching and disease severity. Safety assessments were performed through week 18. RESULTS: A total of 70 patients were randomly assigned in a 1:1 ratio to receive nemolizumab (34 patients) or placebo (36). The initial pruritus score on the numerical rating scale was 8.4 in each group. At week 4, the peak pruritus score on the numerical rating scale was reduced from baseline by 4.5 points (change, -53.0%) in the nemolizumab group, as compared with a reduction of 1.7 points (change, -20.2%) in the placebo group (difference, -32.8 percentage points; 95% confidence interval, -46.8 to -18.8; P<0.001). Results for secondary outcomes were in the same direction as for the primary outcome. Nemolizumab was associated with gastrointestinal symptoms (abdominal pain and diarrhea) and musculoskeletal symptoms. CONCLUSIONS: Nemolizumab resulted in a greater reduction in pruritus and severity of skin lesions than placebo in patients with prurigo nodularis but was associated with adverse events. Larger and longer trials are needed to determine the durability and safety of nemolizumab for the treatment of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT03181503.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, nemolizumab generated promising results in prurigo nodularis, a highly pruritic skin disorder assumed to be related to AD193.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [193]
In the citing paper
“However, this conclusion may not be generalized for a number of itchy skin disorders such as prurigo nodularis in which targeting itch remains promising193,205,210–212.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [193]
Citations
Cites
IL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Pereira, M. P., Steinke, S., Zeidler, C., Forner, C., Riepe, C., Augustin, M., Bobko, S., Dalgard, F., Elberling, J., Garcovich, S., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14570 · Cited by 274
Self-citationEthnic differences and comorbidities of 909 prurigo nodularis patients
Boozalis, E., Tang, O., Patel, S., Semenov, Y. R., Pereira, M. P., Stander, S., Kang, S., & Kwatra, S. G. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.047 · Cited by 189
Self-citationIL-31: A new key player in dermatology and beyond
Bağci, I. S., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.045 · Cited by 160
Chronic Prurigo of Nodular Type: A Review
Zeidler, C., Tsianakas, A., Pereira, M. P., Ständer, H. F., Yosipovitch, G., & Ständer, S. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2774 · Cited by 126
Self-citationPrurigo Nodularis and Its Management
Zeidler, C., Yosipovitch, G., & Ständer, S. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.003 · Cited by 112
Self-citationSteinke, S., Zeidler, C., Riepe, C., Bruland, P., Soto‐Rey, I., Storck, M., Augustin, M., Ивановна, Б. С., Garcovich, S., Legat, F. J., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.044 · Cited by 104
Self-citationItch in dermatomyositis: the role of increased skin interleukin-31
Kim, H. J., Zeidi, M., Bonciani, D., Pena, S. M., Tiao, J., Sahu, S., & Werth, V. P. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16498 · Cited by 94
The pathogenesis of Prurigo nodularis – ‘Super‐Itch’ in exploration
Zeidler, C., & Ständer, S. (2016) · European Journal of Pain · doi:10.1002/ejp.767 · Cited by 91
Self-citationBrenaut, E., Halvorsen, J. A., Dalgard, F. J., Lien, L., Balieva, F., Sampogna, F., Linder, D., Evers, A. W. M., Jemec, G. B. E., Gieler, U., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15145 · Cited by 85
Self-citation
Cited by
Items 101–200 of 281
A case of bullous pemphigoid following administration of anti‐IL ‐31 receptor A antibody
Masuyuki, R., Sato, E., & Imafuku, S. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17171 · Cited by 19
Biologics for atopic diseases: Indication, side effect management, and new developments
Jappe, U., Beckert, H., Bergmann, K., Gülşen, A., Klimek, L., Philipp, S., Pickert, J., Rauber, M. M., Renz, H. E., Taube, C., et al. (2021) · Allergologie · doi:10.5414/alx02197e · Cited by 25
“[178] 2016 2018 2020 2020 – – – – – – – – – 2.”
Neuroimmune Circuits in Allergic Diseases
Cai, H., Zhu, X., & Sokol, C. L. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-032154 · Cited by 19
Neural Regulation of Innate Immunity in Inflammatory Skin Diseases
Huang, X., Li, F., & Wang, F. (2023) · Pharmaceuticals · doi:10.3390/ph16020246 · Cited by 20
Kwatra, S. G., Rodriguez, D. N., Dias-Barbosa, C., Budhiarso, I., Fofana, F., Vernon, M., Gabriel, S., Piketty, C., & Puelles, J. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-00999-9 · Cited by 18
“Psychometric properties of the PP NRS were analyzed using data from a phase 2 multicenter, randomized, placebo-controlled, double-blinded trial of nemolizumab in adults with severe pruritus (NCT03181503) [16].”
MethodSelf-citationA New Era with the Development of Cytokine-Based Therapy for Pruritus
Shibuya, R., Takimoto‐Ito, R., Kambe, N., & Kabashima, K. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.09.023 · Cited by 20
“pruritus in patients with moderate-to-severe prurigo nodularis in a recent randomized phase 2 clinical trial (Ständer et al., 2020).”
BackgroundKunimura, K., & Fukui, Y. (2021) · International Immunology · doi:10.1093/intimm/dxab065 · Cited by 19
“These IL-31-targeted therapies might be applicable to not only AD but also other skin diseases that feature elevation of serum IL-31 levels, such as prurigo nodularis, psoriasis, cutaneous T-cell lymphoma and uremic pruritus (22, 33–38).”
BackgroundIncreased IL-31 expression in serum and tissue protein in prurigo nodularis
Chaowattanapanit, S., Wongjirattikarn, R., Chaisuriya, N., Ungarreevittaya, P., Poosekeaw, P., Winaikosol, K., Choonhakarn, C., Julanon, N., & Salao, K. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221112561 · Cited by 17
Samotij, D., Szczęch, J., Antiga, E., Bonciani, D., Caproni, M., Chasset, F., Dańczak‐Pazdrowska, A., Furukawa, F., Hasegawa, M., Hashizume, H., et al. (2021) · Lupus · doi:10.1177/09612033211016098 · Cited by 17
Self-citationStänder, S., Fofana, F., Dias-Barbosa, C., Rodriguez, D. N., Budhiarso, I., Jabbar‐Lopez, Z. K., Piketty, C., Vernon, M., & Puelles, J. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-00962-8 · Cited by 16
“The psychometric properties of the SD NRS were analyzed using data from a phase 2 randomized controlled trial of nemolizumab in adults with PN (NCT03181503), which received ethical approval for each participating site.”
MethodInfluentialSelf-citationTietz, J., Gunde, T., Warmuth, S., Weinert, C., Brock, M., Simonin, A., Hess, C., Johansson, M., Spiga, F., Muntwiler, S., et al. (2024) · JID Innovations · doi:10.1016/j.xjidi.2024.100258 · Cited by 16
Chronic itch in African Americans: an unmet need
Ingrasci, G., El-Kashlan, N., Alexis, A. F., & Yosipovitch, G. (2021) · Archives of Dermatological Research · doi:10.1007/s00403-021-02255-6 · Cited by 16
Self-citationImprovement of chronic nodular prurigo with baricitinib
Pereira, M. P., Zeidler, C., & Ständer, S. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17991 · Cited by 16
Self-citationDellon, E. S., Simon, D., & Wechsler, M. E. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.01.043 · Cited by 19
Honstein, T., & Werfel, T. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000652 · Cited by 17
Emerging trends and hotspots of the itch research: A bibliometric and visualized analysis
Li, J., Wang, L., Yin, S., Yu, S., Zhou, Y., Lin, X., Jiao, Y., Yu, W., Xia, X., Yang, L., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14514 · Cited by 16
A critical evaluation of nemolizumab for prurigo nodularis
Brooks, S. G., & Yosipovitch, G. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2306225 · Cited by 15
Self-citationCornman, H., Manjunath, J., Reddy, S., Adams, J., Rajeh, A., Samuel, C., Bao, A., Zhao, R., Ma, E. Z., Shumsky, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-58013-x · Cited by 11
“Inclusion criteria for PN patients were modeled after previous clinical trials of PN, including diagnosis of PN by a board-certified dermatologist, at least 20 nodules on bilateral regions of the body, and a WI-NRS score of at least 7 55 .”
MethodVixarelimab in Patients With Prurigo Nodularis
Ständer, S., Yosipovitch, G., Sofen, H. L., Abramzon, D., Galanter, J., Wang, S., & Paolini, J. F. (2025) · JAMA Dermatology · doi:10.1001/jamadermatol.2025.4950 · Cited by 14
Self-citationBahloul, D., Hudson, R. D. A., Balogh, O., Mathias, E., Heywood, B., Hubbuck, E., Diribe, O., McDonald, R., & Bewley, A. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae207 · Cited by 13
Evaluation, management and future perspectives of anal pruritus: a narrative review
Jakubauskas, M., & Dulskas, A. (2023) · European journal of medical research · doi:10.1186/s40001-023-01018-5 · Cited by 15
“These two antibodies were mainly tested on inflammatory dermatoses, thus their effects on idiopathic anal pruritus remains questionable [54, 55].”
BackgroundHashimoto, T., Okuno, S., Okuzawa, M., & Satoh, T. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18942 · Cited by 13
The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases
GIROLOMONI, G., MAURELLI, M., & GISONDI, P. (2022) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.22.07265-6 · Cited by 12
Joel, M. Z., Taylor, M. T., Cornman, H. L., Kambala, A., Reddy, S. V., Gabriel, S., & Kwatra, S. G. (2023) · JAAD International · doi:10.1016/j.jdin.2023.07.009 · Cited by 13
“70 patients with PN treated with nemolizumab for 12 weeks also showed improved sleep quality measured by Numeric Rating Scale scores.(26) Depression and anxiety, both conditions associated with PN, are known contributors to the development of insomnia and other sleep disorders.”
MethodMetz, M., Zeidler, C., Hawro, T., Pereira, M. P., Maurer, M., Bonnekoh, H., Krause, K., Pritchard, T., Kwatra, S. G., Ständer, S., et al. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.5519 · Cited by 12
Self-citationIL ‐4 and IL ‐13 are not involved in IL ‐31‐induced itch‐associated scratching behaviour in mice
Kawai, R., Ichimasu, N., & Katagiri, K. (2024) · Experimental Dermatology · doi:10.1111/exd.15115 · Cited by 14
“Functional inhibition of IL-31 by the IL-31 receptor A antibodies nemolizumab rapidly reduces pruritus in prurigo nodularis, 12 which is characterised by excessive expression of IL31 mRNA.”
BackgroundTherapeutics in chronic pruritus of unknown origin
Ju, T., Labib, A., Does, A. V., & Yosipovitch, G. (2023) · Itch · doi:10.1097/itx.0000000000000064 · Cited by 11
“Its safety pro fi le seems very good with few adverse events that include gastrointestinal symptoms [71] .”
BackgroundSelf-citationAssociation between atopic dermatitis and prurigo nodularis: a systematic review and meta‐analysis
Li, W., Pi, Y., & Xu, J. (2024) · International Journal of Dermatology · doi:10.1111/ijd.17493 · Cited by 11
Yokozeki, H., Murota, H., & Matsumura, T. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf045 · Cited by 11
Liu, T., Bai, J., Wang, S., Ying, S., Li, S., Qiao, J., & Fang, H. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s300975 · Cited by 11
Single-cell RNA sequencing reveals dysregulated fibroblast subclusters in prurigo nodularisPreprint
Patel, J. R., Joel, M. Z., Lee, K. K., Kambala, A., Cornman, H. L., Oladipo, O. O., Taylor, M. T., Deng, J., Parthasarathy, V., Cravero, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.29.526050 · Cited by 13
Dupilumab as a novel treatment option for prurigo nodularis
Nakajima, S., Yonekura, S., Nakamizo, S., Egawa, G., & Kabashima, K. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.011 · Cited by 11
The role of nemolizumab in the treatment of atopic dermatitis for the adult population
Prajapati, S., Flemming, J. P., Khan, D., Han, H., How, B., Rozenberg, S. S., & Feldman, S. R. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2383554 · Cited by 10
Ficheux, A., Brenaut, E., Schut, C., Dalgard, F. J., Bewley, A., van Middendorp, H., Gieler, U., Lien, L., Sampogna, F., Ständer, S., et al. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.12.043 · Cited by 10
Self-citationResolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series
Wieser, J. K., Mercurio, M. G., & Somers, K. E. (2020) · Cureus · doi:10.7759/cureus.8737 · Cited by 15
“Additionally, a recent phase 2 trial involving nemolizumab, which inhibits IL-31 receptor A, suggested efficacy over placebo but was associated with gastrointestinal and musculoskeletal adverse events [14].”
BackgroundComparing the Efficacy of Updated Treatment Choices for Prurigo Nodularis: A Network Meta-Analysis
Wang, X., Jia, Q., Wu, M.-Y., Liu, M., Mi, X., & Li, J. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.12.003 · Cited by 9
Prurigo: review of its pathogenesis, diagnosis, and treatment
Criado, P. R., Ianhez, M., Criado, R. F. J., Nakano, J., Lorenzini, D., & Miot, H. A. (2024) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2023.11.003 · Cited by 17
Jappe, U., Bergmann, K., Brinkmann, F., Faihs, V., Gülşen, A., Klimek, L., Renz, H., Seurig, S., Taube, C., Traidl, S., et al. (2024) · Allergologie select · doi:10.5414/alx02533e · Cited by 13
Janus Kinase Inhibitors for the Treatment of Prurigo Nodularis: A Systematic Review of 211 Patients
Vahabi, S. M., Heidari, S., Pourgholi, E., Memari, H., Hashemnejad, M. A., Ansari, M. S., Tarki, F. E., Sadeghi, B., Soveizi, S., & Etesami, I. (2026) · The Journal of Dermatology · doi:10.1111/1346-8138.70150 · Cited by 12
Emerging drugs for the treatment of chronic pruritic diseases
Fourzali, K. M., Golpanian, R. S., & Yosipovitch, G. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1801632 · Cited by 10
Self-citationMarani, M., Madan, V., Le, T. K., Deng, J., Lee, K. K., Ma, E. Z., & Kwatra, S. G. (2024) · Genes · doi:10.3390/genes15020146 · Cited by 13
“Inclusion criteria for patients with PN were diagnosis by a board-certified dermatologist and the presence of at least 20 nodules on more than one extremity [21].”
BackgroundPatel, J., Deng, J., Kambala, A., Lee, K. K., Cornman, H. L., Parthasarathy, V., Pritchard, T., Chen, S., Hernandez, A., Shin, S. M., et al. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.01.036 · Cited by 9
Geroldinger‐Simić, M., Bayati, S., Pohjanen, E., Sepp, N. T., Nilsson, P., & Pin, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065629 · Cited by 9
“Recently, nemolizumab, a humanized monoclonal antibody targeting the IL31 receptor, has been proven efficient in clinical studies for prurigo nodularis [46].”
BackgroundA systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis
Nilforoushzadeh, M. A., Heidari, N., Ghane, Y., Heidari, A., Hajikarim‐Hamedani, A., Hosseini, S., Jaffary, F., Nobari, M. N., Tavakolzadeh, P., & Nobari, N. N. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01436-9 · Cited by 8
“Nemolizumab therapy was also found to be beneficial for moderate-to-severe PN in another study conducted by Ständer et al. (Ständer et al. 2020b).”
Th2 mRNA gene expression analysis separates Prurigo nodularis into two immune signature groups
Ständer, S., Guttman‐Yassky, E., Yosipovitch, G., Wiegmann, H., Metze, D., Kim, M., DUCA, E. D., Bondensgaard, K., Paolini, J. F., & The LOTUS‐PN Investigators Group (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20812 · Cited by 8
“2,25 Further, our study found significantly increased positive signals for OSM and OSMRß staining in lymphocytes and monocytes from LS samples of patients with PN.”
Self-citationCross-Talk between Neurons and Immune Cells in Pruritus: from Mechanisms To Medicines
Khalil, N. B., Kagan, T., & Yosipovitch, G. (2026) · Current Allergy and Asthma Reports · doi:10.1007/s11882-026-01255-8 · Cited by 9
“Dermal IL-31 expression has been found to correlate with itch intensity in PN patients [ 50], and drugs that block the actions of IL-31, such as nemoli-zumab, have been shown to rapidly decrease itch and over-all disease severity [52].”
Self-citationPrurigo crónico: actualización
Docampo‐Simón, A., Sánchez‐Pujol, M. J., & Salvador, J. F. S. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.11.002 · Cited by 8
Bergqvist, C., Fiani, C., Simantov, A., Lebre, C., Hua, C., Ortonne, N., Wolkenstein, P., & Chosidow, O. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17262 · Cited by 8
Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study
Selvaraj, K. J., Stewart, T., & Frew, J. W. (2023) · JAAD International · doi:10.1016/j.jdin.2023.02.006 · Cited by 8
Raja, A. R., Fazal, Z. Z., & Sethi, A. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09054-1 · Cited by 7
“Although recent studies report less frequent and more delayed need for rescue medication with nemolizumab than placebo [19], our results show no significant differences between the two treatment cohorts.”
Recent Advances of Basophils in Pruritic Skin Diseases
Liu, W., Xu, R., & Wang, F. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.12.005 · Cited by 7
A critical review of dupilumab for adult patients with prurigo nodularis
Soares, G. B., & Yosipovitch, G. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2268291 · Cited by 7
Self-citationPractical Approach for the Diagnosis and Treatment of Chronic Pruritus
Golpanian, R. S., Gonzalez, J. M., & Yosipovitch, G. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2020.05.002 · Cited by 7
Self-citationGurnani, P., Miloh, T., Chandar, J. J., Landau, D., Hajjar, F. M., & Yosipovitch, G. (2021) · Pediatric Dermatology · doi:10.1111/pde.14596 · Cited by 9
Self-citationDivergent in situ expression of IL ‐31 and IL‐31RA between bullous pemphigoid and pemphigus vulgaris
Ergün, E. Z., Aoki, R., Horváth, O. N., Hartmann, D., Satoh, T. K., Calabrese, L., Aksu, A. E. K., Gürel, M. S., Manav, V., Flaig, M. J., et al. (2023) · Experimental Dermatology · doi:10.1111/exd.14842 · Cited by 7
IL‐31 and IL‐31 receptor alpha in pemphigus: Contributors to more than just itch?
Okuno, S., Hashimoto, T., Yamazaki, Y., Okuzawa, M., & Satoh, T. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.16730 · Cited by 7
Prurigo nodularis forecast: Light type 2 inflammation with high chances of fibrosis
Conrad, C., & Schlapbach, C. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.11.003 · Cited by 7
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis
Legat, F. J., Kwatra, S. G., Reich, A., Boulinguez, S., Tsianakas, A., Sauder, M. B., Barbarot, S., Szepietowski, J. C., Conrad, C., Pink, A., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70266 · Cited by 6
“15,16,22 Additionally, the vast majority (>85”
Self-citationEfficacy of dupilumab in chronic prurigo: A multicentre retrospective study
Gael, M., Schoeffler, A., & Bursztejn, A. ‐. (2024) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2024.103336 · Cited by 6
Prurigo crónico nodular: Estudio retrospectivo de 74 casos
Sicre, J. E., Simón, A. D., & Salvador, J. F. S. (2022) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2022.05.018 · Cited by 6
Kupsa, R., Gruber‐Wackernagel, A., Hofer, A., Quehenberger, F., Wolf, P., & Legat, F. J. (2023) · Acta Dermato Venereologica · doi:10.2340/actadv.v103.9403 · Cited by 6
Self-citationTherapeutic outcomes across Janus kinase inhibitors in prurigo nodularis
Avallone, G., Bombelli, A., Valtellini, L., Tavoletti, G., Gallì, B., Rossi, M., Maurelli, M., Girolomoni, G., Gargiulo, L., Narcisi, A., et al. (2025) · Clinical and Experimental Dermatology · doi:10.1093/ced/llaf302 · Cited by 6
Lancz, A., Meznerics, F. A., Árok, R., Lengyel, A. S., Szabó, B., Hegyi, P. J., Kiss, N., & Bánvölgyi, A. (2026) · International Journal of Dermatology · doi:10.1111/ijd.70246 · Cited by 5
“Emerging biologics such as nemolizumab and vixarelimab consistently showed meaningful improvements in pruritus and nodule severity in individual studies [99, 134, 142, 143].”
Abrocitinib for prurigo nodularis: Clinical efficacy and safety profile
Wang, C., Zhang, Q., Yu, L., Chen, L., & Chen, J. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20322 · Cited by 5
PIEZO1 channels in cutaneous free nerve endings: novel insights into itch-scratch-mechanisms
Pereira, M. P., Wiegmann, H., & Ständer, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01271-w · Cited by 5
“In some entities, a severe itch-scratch-cycle develops, as for instance in chronic nodular prurigo (CNPG).(2) More, strong mechanical stimuli may induce pruritic dermatoses in predisposed patients (for example inducible urticaria).”
BackgroundInfluentialSelf-citationPrurito en dermatología. Enfermedades y su tratamiento. Parte 2
Navarro‐Triviño, F. J. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.03.004 · Cited by 7
Farina, N., Campochiaro, C., Lescoat, A., Benanti, G., Luca, G. D. D., Khanna, D., Dagna, L., & Matucci‐Cerinic, M. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2230370 · Cited by 6
“Nemolizumab specifically inhibits IL-31, and it has been mainly evaluated for the treatment of atopic dermatitis and prurigo nodularis with positive results [90,91].”
BackgroundFrom Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies
Prados‐Carmona, Á., Husein‐ElAhmed, H., Navarro‐Triviño, F. J., & Ruíz‐Villaverde, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311487 · Cited by 7
Canine interleukin-31 binds directly to OSMRβ with higher binding affinity than to IL-31RA
Zheng, Y., Zhang, J., Guo, T., Cao, J., Wang, L., Zhang, J., Pang, X., Gao, F., Sun, H., & Xiao, H. (2023) · 3 Biotech · doi:10.1007/s13205-023-03724-7 · Cited by 4
“To date, several monoclonal antibodies (mAb) targeting IL-31 or its receptors have been developed, and two of them have been approved (Kabashima et al. 2018; Marsella et al. 2020; Nemoto et al. 2016; Richards et al. 2020; Stander et al. 2020).”
BackgroundHigh Serum IL-31 Concentration Is Associated with Itch among Renal Transplant Recipients
Krajewski, P. K., Tyczyńska, K. M., Bardowska, K., Olczyk, P., Nowicka‐Suszko, D., Janczak, D., Augustyniak‐Bartosik, H., Krajewska, M., & Szepietowski, J. C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154309 · Cited by 4
“The use of nemolizumab resulted in a greater reduction in itch and severity of skin lesions [54].”
BackgroundMerkel, T., Navarini, A. A., & Mueller, S. M. (2024) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/phpp.12948 · Cited by 4
Thünemann, J., Müller, S., Steinbrink, K., Ständer, S., & Zeidler, C. (2024) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15317 · Cited by 4
Self-citationPrurigo nodularis in 2025: Current and emerging treatments
Brooks, S. G., & Yosipovitch, G. (2025) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2025.03.013 · Cited by 4
Self-citationSerra‐Baldrich, E., Santamaria‐Babí, L. F., & Silvestre, J. F. (2022) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2022.06.001 · Cited by 3
Update zur Therapie der chronischen Prurigo
Zeidler, C., Pereira, M. P., & Ständer, S. (2022) · Die Dermatologie · doi:10.1007/s00105-022-05020-6 · Cited by 3
“2) Nemolizumab Nemolizumab, ein humanisierter monoklonaler Antikörper, richtet sich gegen den IL-31-Rezeptor A, der die Signalübertragung von IL-31 blockiert.”
BackgroundInfluentialSelf-citation[Translated article] Chronic Nodular Prurigo: A Retrospective Study of 74 Cases
Sicre, J. E., Simón, A. D., & Salvador, J. F. S. (2022) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2022.08.012 · Cited by 3
Scratching Beyond the Surface of Itchy Wounds
Yang, T.-L. B., & Kim, B. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.016 · Cited by 3
Ardigò, M., Franceschini, C., Campione, E., Cosio, T., Lanna, C., Bianchi, L., & Milani, M. (2020) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s292636 · Cited by 3
Prurigo Simplex or “Itchy Red Bump” Disease: Review and Case Series
Wallengren, J. (2021) · Acta Dermato Venereologica · doi:10.2340/00015555-3912 · Cited by 3
“Nemolizumab, a humanized antihuman interleukin-31 receptor A monoclonal antibody, has proved promising in a phase II randomized, placebo-controlled trial on chronic prurigo (37, 41).”
BackgroundAbnormal Levels of Cortisol and Cortisone in Patients with Prurigo Nodularis
Chu, L., Wu, Y., Yang, L., Yang, H., Lu, Q., & Deng, H. (2021) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_912_20 · Cited by 3
RetractedDupilumab for Chronic Prurigo in Different Backgrounds: A Case Series
Luo, N., Wang, Q., Lei, M., Li, T., & Hao, P. (2022) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s379231 · Cited by 3
“Nemolizumab, a humanized monoclonal antibody to the IL-31 receptor a, reduced pruritus and lesion severity to a greater extent compared to placebo in a randomized, double-blind Phase 2 trial.(12) Omalizumab is a recombinant humanized anti-IgE monoclonal antibody for chronic spontaneous urticaria,(13) there were two ca…”
Backgroundvon Martial, S., Kok, L., Gründel, S., Augustin, M., Blome, C., Zeidler, C., Steinbrink, K., Ständer, S., & Tsianakas, A. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.2930 · Cited by 3
Self-citationSchuermann, M., Richter, C., Tanadini, M., Steigmiller, K., Burri, E., Guillet, C., Luchsinger, I., Meier-Schiesser, B., Boesch, A., Nägeli, M., et al. (2023) · Dermatology · doi:10.1159/000533799 · Cited by 4
“However, these typically take at least 4 weeks for full effect [20, 21] and are only available in wealthy regions of the world.”
BackgroundThe top 100 most cited contributions on prurigo nodularis: A bibliometric analysis
André, N., & Horev, A. (2023) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2023.10.001 · Cited by 4
The efficacy of topical 0.025% capsaicin gel for the treatment of lichen amyloidosis: A pilot study
Tanabodee, M., Sudtikoonaseth, P., Chayangsu, O., & Wessagowit, V. (2023) · Australasian Journal of Dermatology · doi:10.1111/ajd.14198 · Cited by 3
“…have linked familial cases of cutaneous amyloidosis to mutations in genes involved in IL-31 signalling, such as OMSR, IL31RA and GPNMB. 2 Nemolizumab, a monoclonal anti- IL-31 antibody, has shown promise in treating itch-related skin conditions 3 and may be effective for cutaneous amyloidosis.”
BackgroundRecent advances in treatment of prurigo nodularis
Chen, C., & Hu, S. C. (2024) · Dermatologica Sinica · doi:10.4103/ds.ds-d-24-00100 · Cited by 7
Biologics for Allergic Dermatologic Diseases
Bilimoria, S. N., & Lio, P. (2020) · Current Allergy and Asthma Reports · doi:10.1007/s11882-020-00923-7 · Cited by 3
Pathophysiology, diagnosis, and management of chronic pruritus
Ahn, Y. H., & Kang, H. (2021) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2021.9.4.189 · Cited by 3
Reversal of the disease signature in prurigo nodularis by blocking the itch cytokine
Sonkoly, E. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.02.009 · Cited by 3
Sofen, H. L., Bissonnette, R., Yosipovitch, G., Silverberg, J. I., Tyring, S. K., Loo, W. J., Zook, M. B., Lee, M., Zou, L., Jiang, G.-L., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4184786 · Cited by 3
Self-citationA Case of Prurigo Nodularis Treating by Acupuncture
Wu, D., & Dong, G.-R. (2021) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s336109 · Cited by 2
New and Emerging Pharmacotherapies for Pruritus: A Systematic Review and Network Meta-Analysis
Li, H., Arthur, A., Forouzandeh, M., Pomputius, A. F., Cuervo‐Pardo, L., & Montanez-Wiscovich, M. E. (2025) · Dermatitis · doi:10.1089/derm.2023.0419 · Cited by 3
Nemolizumab (Nemluvio®) for prurigo nodularis
Royeck, S., & Ständer, S. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.06.004 · Cited by 2
Self-citationWu, Y., Wasikowski, R., Patrick, M. T., Gharaee‐Kermani, M., Xing, X., Billi, A. C., Kahlenberg, J. M., Julia, V., Gudjonsson, J. E., & Tsoi, L. C. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.08.026 · Cited by 3
Wu, J., Zhang, K., Liao, Y. S. J., Yang, C., Ge, J., Wu, C., Yu, B., Zhong, W., Shao, Y., & Dou, X. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70263 · Cited by 2
“Based on IGA scores [24], all PN patients had moderate ‐ to ‐ severe disease with severe pruritus and high disease activity.”
Takechi, T., Shimizu, J., Kabashima, K., & Ieiri, I. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01554-4 · Cited by 2
Vieira, A. C. P., Akabane, M. A. C. C., Caletti, G. C. G., Heffel, K. K., & Silva, A. T. O. E. (2025) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2025.501210 · Cited by 2
Feng, W., Wang, D., Tan, K., & Zhang, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1626395 · Cited by 2
“Specifically, the most notable absolute difference was observed in Ständer 2025 trial ( n = 282, ARD+8.9% with placebo AE rate 65.3%), while the paradoxical result in Ständer 2020 trial ( n = 70, ARD-5.”
InfluentialTherapeutic advances in pruritus as a model of personalized medicine
Auyeung, K. L., Kubofcik, R., & Kim, B. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70169 · Cited by 3
“9 Such studies provided the rationale for anti- IL-31R α mAb nemolizumab to advance rapidly in clinical development with early success in phase 2 clinical trials for PN. 35,36 In parallel, with the identification of sensory neuronal IL-4R α signalling as a key mechanism of itch in AD, dupilumab bypassed phase 2 clinic…”
InfluentialModerne systemische Therapie des Pruritus
Metz, M., & Pereira, M. P. (2020) · Der Hautarzt · doi:10.1007/s00105-020-04604-4 · Cited by 2
Metadata
- Authors
- Ständer, S., Yosipovitch, G., Legat, F. J., Lacour, J.-P., Paul, C., Narbutt, J., Bieber, T., Misery, L., Wollenberg, A., Reich, A., Ahmad, F., & Piketty, C.
- Affiliations
- University Hospital Bonn (DE)
- University of Graz (AT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-20
- Volume
- 382
- Issue
- 8
- Pages
- 706-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3008008049
- Cited by
- 281
- References
- 18
- Citations by year
- 2026: 22 · 2025: 36 · 2024: 39 · 2023: 63 · 2022: 40 · 2021: 52 · 2020: 28
- FWCI
- 33.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nestle Skin Health
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
- Keywords
- prurigo nodularis, nemolizumab, monoclonal antibodies, pruritus, skin lesions, adverse events, gastrointestinal symptoms, musculoskeletal symptoms, treatment safety, treatment efficacy, numerical rating scale
- MeSH terms
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Injections, Subcutaneous, Male, Middle Aged, Muscular Diseases, Prurigo, Pruritus, Young Adult, Antibodies, Monoclonal, Humanized, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.